PH24813A - Drug delivery system and method of making the same - Google Patents

Drug delivery system and method of making the same

Info

Publication number
PH24813A
PH24813A PH36268A PH36268A PH24813A PH 24813 A PH24813 A PH 24813A PH 36268 A PH36268 A PH 36268A PH 36268 A PH36268 A PH 36268A PH 24813 A PH24813 A PH 24813A
Authority
PH
Philippines
Prior art keywords
making
delivery system
same
drug delivery
varying
Prior art date
Application number
PH36268A
Other languages
English (en)
Inventor
Thomas R Tice
Richard M Gilley
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22163252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH24813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of PH24813A publication Critical patent/PH24813A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
PH36268A 1987-08-03 1987-12-18 Drug delivery system and method of making the same PH24813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/081,289 US4897268A (en) 1987-08-03 1987-08-03 Drug delivery system and method of making the same

Publications (1)

Publication Number Publication Date
PH24813A true PH24813A (en) 1990-10-30

Family

ID=22163252

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36268A PH24813A (en) 1987-08-03 1987-12-18 Drug delivery system and method of making the same

Country Status (14)

Country Link
US (1) US4897268A (fr)
EP (1) EP0302582B2 (fr)
JP (1) JPS6442420A (fr)
AT (1) ATE109000T1 (fr)
AU (1) AU611662B2 (fr)
BR (1) BR8801242A (fr)
CA (1) CA1302260C (fr)
DE (1) DE3850823T3 (fr)
ES (1) ES2056915T5 (fr)
GR (1) GR3026376T3 (fr)
IL (1) IL86221A (fr)
MX (1) MX162898B (fr)
NZ (1) NZ225608A (fr)
PH (1) PH24813A (fr)

Families Citing this family (399)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US20030161889A1 (en) * 1984-03-16 2003-08-28 Reid Robert H. Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
US5762965A (en) * 1984-03-16 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
ES2084698T5 (es) * 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
CH679207A5 (fr) * 1989-07-28 1992-01-15 Debiopharm Sa
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5484584A (en) * 1990-10-02 1996-01-16 Board Of Regents, The University Of Texas System Therapeutic and diagnostic use of modified polymeric microcapsules
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5102402A (en) 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5153002A (en) * 1991-03-04 1992-10-06 University Of Montreal Biocompatible gradient controlled release implant
AU8303691A (en) 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993017668A1 (fr) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Microspheres a liberation regulee contenant l'hormone adrenocorticotrope (acth)
US5510077A (en) * 1992-03-19 1996-04-23 Dinh; Thomas Q. Method of making an intraluminal stent
US5571166A (en) * 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AU4932493A (en) * 1992-09-25 1994-04-26 Dynagen, Inc. An immunobooster for delayed release of immunogen
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
UA61046C2 (en) * 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
EP0681478A4 (fr) * 1993-03-22 2000-09-06 U S Government Vaccins contre des maladies causees par des organismes enteropathogenes utilisant des antigenes encapsules dans des microspheres biodegradables et biocompatibles
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
EP0804249A2 (fr) * 1994-03-15 1997-11-05 Brown University Research Foundation Systeme de liberation de genes polymeres
DK0754032T3 (da) * 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
ES2271449T3 (es) 1995-09-01 2007-04-16 Corixa Corporation Compuestos para inmunoterapia y diagnostico de la tuberculosis.
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
EP0862419B2 (fr) 1995-11-09 2010-11-17 Microbiological Research Authority Adn microencapsule s'appliquant dans des procedes de vaccination et de therapie genique
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2192773C (fr) 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP0981624A2 (fr) 1997-02-12 2000-03-01 Corixa Corporation ANTIGENES $i(LEISHMANIA) UTILISES DANS LE TRAITEMENT ET LE DIAGNOSTIC DE LA LEISHMANIOSE
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
EP1042360A2 (fr) 1997-12-24 2000-10-11 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1792988A3 (fr) 1998-03-18 2007-08-22 Corixa Corporation Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
AU3555599A (en) 1998-04-13 1999-11-01 Luminex Corporation Liquid labeling with fluorescent microparticles
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
KR100293504B1 (ko) 1998-06-05 2001-07-12 김윤 서방형전립선염치료제조성물
EP1100473A2 (fr) 1998-07-28 2001-05-23 InnerDyne, Inc. Dispositifs absorbables d'apport pour curietherapie et chimiotherapie et procedes correspondants
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US6013122A (en) * 1998-08-18 2000-01-11 Option Technologies, Inc. Tattoo inks
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU775879C (en) * 1998-11-20 2005-03-10 Freedom-2, Inc. Permanent, removable tissue markings
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1049848A1 (zh) 1999-04-02 2003-05-30 科里克萨有限公司 用於治療和診斷肺癌的化合物和方法
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
EP1229931A4 (fr) * 1999-10-07 2003-05-28 Corixa Corp Proteines hybrides de mycobacterium tuberculosis
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US6575888B2 (en) 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
MXPA02007938A (es) 2000-02-17 2003-02-10 3M Innovative Properties Co Sistema de suministro, composiciones y metodos, que utilizan un polimero biodegradable preformado.
DE60143425D1 (de) 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040142475A1 (en) * 2000-06-02 2004-07-22 Barman Shikha P. Delivery systems for bioactive agents
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1961819A3 (fr) 2000-06-28 2008-11-12 Corixa Corporation Composition et procédés pour la thérapie et le diagnostic du cancer des poumons
US20040158317A1 (en) * 2000-07-18 2004-08-12 Pharmasonics, Inc. Coated stent with ultrasound therapy
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2004516262A (ja) 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
US7077859B2 (en) * 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20020082679A1 (en) * 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
US20050125054A1 (en) * 2000-12-22 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
US6939375B2 (en) 2000-12-22 2005-09-06 Avantac Vascular Corporation Apparatus and methods for controlled substance delivery from implanted prostheses
US20030033007A1 (en) * 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (fr) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Proteines de fusion d'immunoglobuline de domaine de liaison
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7018371B2 (en) * 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
EP1515982A4 (fr) 2001-05-09 2005-10-26 Corixa Corp Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
WO2003000156A1 (fr) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
EP1417236A4 (fr) 2001-07-10 2010-03-17 Corixa Corp Compositions et procedes destines a l'administration de proteines et d'adjuvants encapsules dans des microspheres
AU2002322719A1 (en) * 2001-07-26 2003-02-17 Avantec Vascular Corporation Delivery of therapeutic capable agents
ES2307779T3 (es) * 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
CA2460535A1 (fr) 2001-09-13 2003-03-20 Ansell Healthcare Products, Inc. Revetement a microcapsules pour gants
EP2305312B1 (fr) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
PT1461054E (pt) 2001-12-11 2010-08-09 Pasteur Institut Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária
CA2860702C (fr) 2001-12-17 2019-02-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
US7736391B2 (en) 2003-02-06 2010-06-15 Tonaba Healthscience Ii, Llc Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
CA2889013C (fr) 2003-03-07 2018-07-17 Dsm Ip Assets B.V. Hydrolases, acides nucleiques les codant, et procedes de fabrication et d'utilisation correspondants
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US20070010702A1 (en) * 2003-04-08 2007-01-11 Xingwu Wang Medical device with low magnetic susceptibility
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
BRPI0409032A (pt) 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP1636270B1 (fr) 2003-06-16 2016-07-20 UCB Pharma S.A. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
BRPI0412735A (pt) * 2003-07-18 2006-09-26 Baxter Int métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US8900636B2 (en) * 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
CA2556753C (fr) 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions et methodes de regulation du sommeil
ATE534424T1 (de) * 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005110425A1 (fr) 2004-04-15 2005-11-24 Alkermes, Inc. Dispositif à libération contrôlée à base de polymère
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
EP2335689A1 (fr) * 2004-05-12 2011-06-22 Baxter International Inc. Méthode de production des microsphères d'acide nucléique
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112893A1 (fr) * 2004-05-12 2005-12-01 Baxter International Inc. Microsphères contenant des protéines et présentant un potentiel d’injectabilité à d’importants degrés de concentration de l’agent concerné
JP2007537288A (ja) * 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
CA2837748C (fr) 2004-05-25 2016-03-08 Oregon Health And Science University Vaccination du virus de l'immunodeficience simienne (siv) et du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de rhcmv et hcmv
US20060264411A1 (en) * 2005-05-20 2006-11-23 Eldridge Gary R Control of biofilm formation
EP3203241A1 (fr) 2004-07-14 2017-08-09 The Regents of The University of California Biomarqueurs pour la détection précoce du cancer des ovaires
US20060014285A1 (en) * 2004-07-14 2006-01-19 Eldridge Gary R Methods and compositions for inhibiting biofilms
US7604978B2 (en) 2004-07-14 2009-10-20 Sequoia Sciences, Inc. Inhibition of biofilm formation
US9132116B2 (en) * 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
EP1781264B1 (fr) * 2004-08-04 2013-07-24 Evonik Corporation Procede de production de systemes d'administration, et systemes d'administration
CA2580078A1 (fr) 2004-09-14 2006-03-23 Gary R. Eldridge Composes, compositions et procedes destine a reguler des films biologiques et a prevenir des infections bacteriennes
CA2587084C (fr) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation de la valeur adaptative reproductive au moyen de codons synonymes employes moins frequemment
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
KR101301429B1 (ko) 2004-11-23 2013-08-30 아다마스 파마슈티칼스, 인코포레이티드 서방성 코팅 또는 매트릭스 및 ｎｍｄａ 수용체 길항제를포함하는 조성물, 대상에 대한 상기 ｎｍｄａ 길항제의투여 방법
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (fr) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition et methode pour traiter des affections neurologiques
US8287583B2 (en) * 2005-01-10 2012-10-16 Taheri Laduca Llc Apparatus and method for deploying an implantable device within the body
US20070150051A1 (en) * 2005-01-10 2007-06-28 Duke Fiduciary, Llc Vascular implants and methods of fabricating the same
CA2593682C (fr) 2005-01-10 2016-03-22 Neose Technologies, Inc. Facteur de stimulation de colonie de granulocytes glycopegylatees
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9050393B2 (en) * 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1701165A1 (fr) 2005-03-07 2006-09-13 Johannes Dr. Coy Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
WO2006104890A2 (fr) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccins destines a lutter contre une infection a chlamydia
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
EP1885335A1 (fr) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Microparticules a surface modifiee et procedes de formation et d'utilisation associes
KR20130110233A (ko) 2005-04-29 2013-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
US7968694B2 (en) 2005-07-01 2011-06-28 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
KR20130024987A (ko) * 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
WO2007079755A1 (fr) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Ré-immunisation et conception d'anticorps
EP1981905B1 (fr) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccin contre chlamydia
EP2216403A3 (fr) 2006-02-02 2010-11-24 Verenium Corporation Estérases et acides nucléiques associés et procédés
WO2007109583A2 (fr) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions et méthodes pour la prévention ou le traitement de maladie néoplasique chez un sujet mammalien
JP5524610B2 (ja) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
DK2027158T3 (da) 2006-05-02 2013-01-14 Carviar Aps Metode til immunisering af en fugleart
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
EP2418223A3 (fr) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Protéines de liaison polyvalente à chaîne unique avec une fonction effectrice
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
JP5118139B2 (ja) 2006-08-04 2013-01-16 バクスター・インターナショナル・インコーポレイテッド 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
CA2665480C (fr) 2006-10-04 2019-11-12 Novo Nordisk A/S Glycopeptides et sucres pegyles a liaison glycerol
MX2009003661A (es) * 2006-10-06 2009-04-22 Baxter Int Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas.
JP2010517703A (ja) 2007-02-09 2010-05-27 タヘリ ラドュカ エルエルシー 血管移植片およびそれを加工する方法
JP5744513B2 (ja) * 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
UA99830C2 (uk) * 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
CA2691819A1 (fr) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Peptides de liaison comprenant un domaine de liaison specifique c-terminal
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20110172305A1 (en) * 2007-10-02 2011-07-14 Ester Fride Endocannabinoids for Enhancing Growth and Development in Infants
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
JP2011503213A (ja) * 2007-11-19 2011-01-27 カプスレイテッド システムズ インコーポレイテッド マイクロ粒子を使用する局所麻酔薬の持続放出および手術適用方法
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
WO2009085952A1 (fr) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Procédé pour préparer des microparticules ayant un faible volume de solvant résiduel
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
EP3023502A1 (fr) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions et procédés pour détecter des mutations egfr dans le cancer
PT2132228E (pt) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
ES2686708T3 (es) 2008-04-18 2018-10-19 Baxter International Inc. Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición
EP2123748A1 (fr) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadénylate synthétase 3 pour prévenir et traiter une infection par virus à ARN à brin unique de sens positif
US8765162B2 (en) 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
BRPI0919811B1 (pt) 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
US20100216948A1 (en) * 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
CA2750003A1 (fr) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Systeme a liberation controlee de melange polymeres
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
WO2010121081A1 (fr) 2009-04-15 2010-10-21 Bmg Pharma Llc Compositions de sel minéral/acide sulfonique et procédés d'utilisation
HUE031051T2 (en) * 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8911766B2 (en) * 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
EP2292260A1 (fr) 2009-08-13 2011-03-09 Institut Pasteur Utilisation de mycobactérie bois tuée par lyophilisation étendue pour la prévention ou le traitement de l'athérosclérose
US20120244185A1 (en) 2009-09-16 2012-09-27 Vaxart ,Inc. Immunization strategy to prevent h1n1 infection
BR112012006103B8 (pt) * 2009-09-17 2021-05-25 Evonik Corp dispositivo de implante e kit
EP2480200A2 (fr) * 2009-09-22 2012-08-01 Evonik Degussa Corporation Dispositifs d'implants présentant différentes configurations de charge de l'agent bioactif
EP3735944A1 (fr) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
CA2776173A1 (fr) 2009-09-30 2011-04-07 Nicholas Marini Cofacteurs et procedes d'utilisation chez des sujets
CA2778678A1 (fr) 2009-10-30 2011-05-05 Cns Therapeutics, Inc. Molecules de neurturine ameliorees
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
CN102858962A (zh) 2009-11-19 2013-01-02 索利斯拜欧代因公司 用于增加多肽稳定性和活性的组合物及相关方法
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
CN102812023A (zh) 2010-01-13 2012-12-05 韩国巴斯德研究所 抗感染吡啶并(1,2-a)嘧啶类
HRP20161608T1 (hr) 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
WO2011116396A2 (fr) 2010-03-19 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Fragments de facteur de croissance d'hépatocyte qui fonctionnent comme agonistes et antagonistes du récepteur met puissant
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012018387A2 (fr) 2010-08-02 2012-02-09 Population Diagnotics, Inc. Compositions et méthodes de recherche de mutations causales dans des troubles génétiques
AU2011332815A1 (en) 2010-11-23 2013-05-30 Presage Biosciences, Inc. Therapeutic methods and compositions for solid delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012122391A1 (fr) 2011-03-08 2012-09-13 3-V Biosciences, Inc. Modulateurs hétérocycliques de la synthèse des lipides
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
AU2012271336B2 (en) 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
PH12014500198A1 (en) 2011-07-15 2017-02-10 Nusirt Sciences Inc Compositions and methods for modulating metabolic pathways
US8324264B1 (en) 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
WO2013054200A2 (fr) 2011-10-10 2013-04-18 The Hospital For Sick Children Méthodes et compositions de dépistage et de traitement de troubles du développement
US20140323907A1 (en) 2011-10-28 2014-10-30 Jason Frazier Methods for drug delivery
EP2773779B1 (fr) 2011-11-04 2020-10-14 Population Bio, Inc. Méthodes et compositions pour le diagnostic, le pronostic et le traitement d'états neurologiques
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
WO2013119856A1 (fr) 2012-02-07 2013-08-15 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
DK2812452T3 (da) 2012-02-09 2020-06-29 Population Bio Inc Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
WO2013130773A2 (fr) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions de microbiota et leurs procédés associés
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2895621B1 (fr) 2012-09-14 2020-10-21 Population Bio, Inc. Procédés et compositions pour le diagnostic, le pronostic et le traitement d'états neurologiques
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
WO2014113404A1 (fr) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Traitement de maladies pulmonaires
US9585876B2 (en) 2013-03-15 2017-03-07 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2014210546A1 (fr) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Système polymère biocompatible pour le traitement ciblé de troubles thrombotiques et hémostatiques
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2014368945C1 (en) 2013-12-20 2019-05-16 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
ES2913858T3 (es) 2014-01-07 2022-06-06 Sagimet Biosciences Inc Moduladores heterocíclicos de síntesis de lípidos para uso contra el cáncer e infecciones virales
CR20160369A (es) 2014-01-21 2016-10-05 Immune Desing Corp Composiciones para uso en el tratamiento de afecciones alérgicas
EA033248B1 (ru) 2014-02-20 2019-09-30 Вэксарт, Инк. Композиция и способ индукции иммунного ответа
JP2017506651A (ja) 2014-02-27 2017-03-09 ニューサート サイエンシーズ， インコーポレイテッド 脂肪肝の低減または予防のための組成物および方法
EP3117004A4 (fr) 2014-03-14 2017-12-06 University of Washington Éléments isolateurs génomiques et leurs utilisations
EP3122375B1 (fr) 2014-03-28 2021-03-03 University of Washington through its Center for Commercialization Vaccins contre le cancer du sein et des ovaires
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016054240A1 (fr) 2014-09-30 2016-04-07 Sean Dalziel Combinaisons à dose fixe pour le traitement de maladies virales
WO2016061199A2 (fr) 2014-10-14 2016-04-21 Research Development Foundation Procédé de génération d'enzymes génétiquement modifiées
EP4529950A3 (fr) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Procédés et compositions se rapportant à un traitement microbien de troubles
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CA2979696A1 (fr) 2015-03-19 2016-09-22 3-V Biosciences, Inc. Modulateurs heterocycliques de synthese de lipides
JP6912394B2 (ja) 2015-06-12 2021-08-04 バクサート インコーポレイテッド Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
EP3383418B1 (fr) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Peptides slc45a2 pour l'immunothérapie
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
WO2017192743A1 (fr) 2016-05-04 2017-11-09 Abilita Bio, Inc. Procédés et plate-forme pour préparer des protéines membranaires polytopiques
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
CA3023271A1 (fr) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
WO2018102743A1 (fr) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11678967B2 (en) 2017-02-28 2023-06-20 Provasctec Limited Intravascular cell therapy device
WO2018200885A1 (fr) 2017-04-26 2018-11-01 Neurocentria, Inc. Compositions de magnésium et méthodes d'utilisation
CA3066915A1 (fr) 2017-06-11 2018-12-20 Molecular Express, Inc. Methodes et compositions destinees a des formulations vaccinales contre des troubles lies a une substance, et leurs utilisations
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019046646A1 (fr) 2017-08-30 2019-03-07 Whole Biome Inc. Methodes et compositions pour le traitement de troubles associés au microbiome
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
CN110123789A (zh) * 2018-02-02 2019-08-16 山东墨海生物科技有限公司 一种载利培酮的plga微球混合物及其制备方法
KR20200141986A (ko) 2018-02-12 2020-12-21 다이어비티스-프리, 인크. 개선된 길항성 항-인간 cd40 단클론 항체
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
WO2020001657A1 (fr) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions et méthodes de traitement de la neuropathie optique héréditaire de leber
JP2021529001A (ja) 2018-06-29 2021-10-28 ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーＷｕｈａｎ Ｎｅｕｒｏｐｈｔｈ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ レーベル遺伝性視神経症を治療するための組成物及び方法
CA3106315A1 (fr) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Procedes et compositions pour prise de greffe microbienne
EP4177356B1 (fr) 2018-08-08 2024-05-08 PML Screening, LLC Procédés d'évaluation du risque de développer une maladie virale à l'aide d'un test génétique
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020067887A1 (fr) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Inhibition spécifique de la janus kinase 3 (jak3) pour moduler des réponses immunitaires antitumorales
WO2020102454A1 (fr) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Peptides ciblant le cd40 et leurs utilisations
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
TW202208418A (zh) 2020-05-21 2022-03-01 美國德州系統大學評議委員會 具有vgll1特異性之t細胞受體及其用途
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
WO2022051023A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Technologie de vaccin hybride à arn atténué vivant
WO2022051024A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Vaccins à base d'arn à adjuvant génétique
WO2022234003A1 (fr) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Polypeptides se liant à cd33 avec protéine stefin a
WO2023280157A1 (fr) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 Construction et utilisation d'anticorps anti-vegf dans un système d'expression in vivo
EP4382601A4 (fr) 2021-08-06 2025-07-30 Wuhan Neurophth Biotechnology Ltd Company Composition et méthode de traitement de la neuropathie optique héréditaire de leber provoquée par la mutation nd4
EP4413038A1 (fr) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Affimers de liaison à pd-l1
EP4412711A1 (fr) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Polypeptides sériques de liaison pd-l1 prolongés à demi-vie
EP4477665A4 (fr) 2022-02-10 2025-08-20 Affyxell Therapeutics Co Ltd Variants protéiques de stéfine a se liant de manière spécifique à cd40l et leurs utilisations
EP4514389A1 (fr) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Méthodes et compositions pour le traitement de maladies et de troubles à éosinophiles
WO2023218243A1 (fr) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Protéines de fusion de liaison lag-3/pd-l1
EP4583841A1 (fr) 2022-09-09 2025-07-16 Access to Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR615662A (fr) * 1927-01-13
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
GB1332505A (en) * 1970-10-16 1973-10-03 Ethicon Inc Sutures and other surgical aids
US3736646A (en) * 1971-10-18 1973-06-05 American Cyanamid Co Method of attaching surgical needles to multifilament polyglycolic acid absorbable sutures
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
NO139560C (no) * 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
US3826796A (en) * 1972-12-20 1974-07-30 American Home Prod P-glu-his-leu-arg-pro-gly-nh2 and intermediates
US3824227A (en) * 1973-04-11 1974-07-16 American Home Prod Decapeptide (d-phe)2 analog of luteinizing hormones releasing factor and intermediates thereof
US3991766A (en) * 1973-05-31 1976-11-16 American Cyanamid Company Controlled release of medicaments using polymers from glycolic acid
FR2238700B1 (fr) * 1973-07-24 1977-10-14 Takeda Chemical Industries Ltd
JPS5726506B2 (fr) * 1974-03-08 1982-06-04
AT347054B (de) * 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
DE2453886A1 (de) * 1973-11-16 1975-05-28 Ciba Geigy Ag Verfahren zur einkapselung von mit wasser nicht mischbaren substanzen
US4033938A (en) * 1974-01-21 1977-07-05 American Cyanamid Company Polymers of unsymmetrically substituted 1,4-dioxane-2,5-diones
US3892723A (en) * 1974-02-04 1975-07-01 American Home Prod P-Glu-Trp-Ser-Tyr-D-Pgl-Leu-Arg-Pro-Gly-NH{HD 2 {B and intermediates
US3896105A (en) * 1974-04-01 1975-07-22 American Home Prod (n-propionyl) -gly-cys-lys-asn-phe-phe-trp-lys-thr-phe-thr-ser-cys-oh and intermediates
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4076798A (en) * 1975-05-29 1978-02-28 American Cyanamid Company High molecular weight polyester resin, the method of making the same and the use thereof as a pharmaceutical composition
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
US4010196A (en) * 1975-06-25 1977-03-01 American Home Products Corporation Linear polyester salts
US4066568A (en) * 1975-08-07 1978-01-03 Nippon Pulp Industry Company Limited Method of producing microcapsules
US4118470A (en) * 1976-06-01 1978-10-03 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
US4107071A (en) * 1977-02-16 1978-08-15 Capsulated Systems, Inc. Method of producing microcapsules and resulting product
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
GB2026976B (en) * 1978-08-04 1982-11-03 Damon Corp Process for preparing semipermeable microcapsules
CA1143289A (fr) * 1978-10-17 1983-03-22 Lee R. Beck Systeme de liberation de medicaments sous forme de microparticules
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0265457A4 (fr) * 1986-04-10 1989-07-26 Daratech Pty Ltd Vaccin et implant.

Also Published As

Publication number Publication date
AU611662B2 (en) 1991-06-20
US4897268A (en) 1990-01-30
DE3850823T3 (de) 1998-07-09
IL86221A (en) 1992-08-18
BR8801242A (pt) 1989-02-21
MX162898B (es) 1991-07-08
AU1099288A (en) 1989-02-09
EP0302582A1 (fr) 1989-02-08
DE3850823D1 (de) 1994-09-01
HK1007490A1 (en) 1999-04-16
ES2056915T5 (es) 1998-04-01
IL86221A0 (en) 1988-11-15
GR3026376T3 (en) 1998-06-30
ATE109000T1 (de) 1994-08-15
JPS6442420A (en) 1989-02-14
EP0302582B1 (fr) 1994-07-27
ES2056915T3 (es) 1994-10-16
EP0302582B2 (fr) 1997-12-17
CA1302260C (fr) 1992-06-02
NZ225608A (en) 1990-12-21
DE3850823T2 (de) 1994-11-17

Similar Documents

Publication Publication Date Title
GR3026376T3 (en) Drug delivery system and method of making the same.
EP1077070A3 (fr) Compositions de médicaments par voie orale
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
DK288987D0 (da) Et afgivelsessystem til doseringsformerne forhalet afgivelse, samt dettes fremstilling
LTIP1654A (en) Protein, biologically active hormone, pharmaceutical preparation
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
EP0202819A3 (fr) Dispositif pour la libération d'une substance active et son procédé de fabrication
NZ221390A (en) Biodegradable implant containing estradiol and poly(lactide-co-glycolide) polymer: method of administration and preparation
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
NZ262679A (en) Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
AU8199187A (en) A liquid dosage form for oral administration of a pharmaceutically active substance
EP0160501A3 (fr) Composé intranasal à effet prolongé et méthode d'utilisation
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
EP0211601A3 (fr) Stabilisation d'hormones de croissance
PT83241B (pt) Processo para a preparacao de composicoes de drogas de matriz polimerica, capazes de mascarar o sabor de um ingrediente activo, contendo um polimero tendo uma serie de grupos acido e ester carboxilicos
IL87778A (en) Topical pharmaceutical compositions in the form of a hydrogel containing stabilized therapeutically active proteins and their preparation
EP0236002A3 (en) Pharmaceutical composition comprising a medicament and a water-swellable polymer
IE882774L (en) Trans-mucosal drug delivery formulations
MY103532A (en) A liquid dosage form for oral administration of a pharmaceutically active substance